Skip to main content

Table 2 Bivariate Spearman correlation between calprotectin and other biochemical markers and metabolic features in patients with and without metabolic syndrome

From: Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients

 

Metabolic syndrome (n = 243)

No metabolic syndrome (n = 62)

 

ρ

P

ρ

P

Age (years)

−0.179

0.005

−0.138

0.294

Weight (kg)

0.199

0.002

0.317

0.014

Height (m)

−0.129

0.046

−0.211

0.106

BMI (kg/m2)

0.252

<0.001

0.446

<0.001

Waist circumference (cm)

0.237

0.001

0.257

0.047

Hip circumference (cm)

0.230

<0.001

0.285

0.027

Diabetes duration (years)

−0.172

0.008

0.092

0.486

CIMT (mm)

−0.114

0.079

−0.168

0.200

Fasting p-glucose (mmol/L)

−0.148

0.021

−0.069

0.601

HbA1c (%)

−0.037

0.564

−0.052

0.691

Fasting C-peptide (pmol/L)

0.081

0.212

0.177

0.176

Fasting insulin (pmol/L)

0.169

0.009

0.247

0.057

Total cholesterol conc. (mmol/L)

−0.072

0.268

0.084

0.523

LDL-cholesterol conc. (mmol/L)

0.002

0.978

0.131

0.318

HDL-cholesterol conc. (mmol/L)

−0.151

0.019

−0.259

0.045

Triglycerides (mmol/L)

0.018

0.779

0.289

0.025

Creatinine (μmol/L)

0.000

0.995

0.022

0.868

hs-CRP (mg/L)

0.415

<0.001

0.346

0.007

HOMA-IR

0.110

0.088

0.169

0.197

SSS

0.136

0.035

0.222

0.088

  1. Statistical significant results are shown in bold.